Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03193047 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
A Phase 2 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT03193047 is a Phase 2 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 59 participants.
The verdict
NCT03193047, a Phase 2 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if bempedoic acid (ETC-1002) 180mg added to PCSK9 inhibitor (evolocumab) therapy is effective and safe in patients with elevated LDL cholesterol.
Interventions
- OTHER placebo
- DRUG evolocumab
- DRUG bempedoic acid 180mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2017-04-07 |
| Est. Completion | 2018-02-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03193047
The ClinicalTrials.gov registry entry for NCT03193047 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT03193047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03193047 about?
NCT03193047 is a clinical study titled "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy". The purpose of this study is to determine if bempedoic acid (ETC-1002) 180mg added to PCSK9 inhibitor (evolocumab) therapy is effective and safe in patients with elevated LDL cholesterol.
What is the current status of trial NCT03193047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2017-04-07. Estimated completion is 2018-02-19.
What interventions are being tested in trial NCT03193047?
The interventions under investigation include: placebo (OTHER), evolocumab (DRUG), bempedoic acid 180mg (DRUG).
Who is sponsoring clinical trial NCT03193047?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.